Table 3.
Primary prevention of cancer-associated venous thromboembolic event in gastrointestinal cancers
| Study | Cancer | n | VTE placebo | VTE LMWH | VTE U-LMWH | RR |
| PROTECHT1 | Gastorintestinal2 | 148/272 | 2.7% | 1.5% | -44% | |
| Agnelli et al[68], 2009 | Pancreas | 17/36 | 5.9% | 8.3% | 40% | |
| SAVE-ONCO | Colo-rectal | 461/464 | 2.0% | 1.1% | -45% | |
| Agnelli et al[69], 2012 | Pancreas | 128/126 | 10.9% | 2.4% | -78% | |
| Stomach | 207/204 | 1.9% | 0.5% | -75% | ||
| FRAGEM | Pancreas | 60/63 | 23% | 3.4% | -85% | |
| Maraveyas et al[70], 2012 | ||||||
| CONKO 004 | Pancreas | 152/160 | 9.9% | 1.3% | -87% | |
| Pelzer et al[71], 2015 |
1
Randomization 1:2;
2
Gastric (n = 40/58), colon (n = 79/156) and rectal (n = 29/58) cancers. LMWH: Low molecular weight heparin; U-LMWH: Ultra-LMWH; RR: Relative risk; VTE: Venous thromboembolic event.